We lack more up-to-date studies that reflect the lower use of corticosteroids or the impact of TPO-RA; therefore, we do not know exactly the mortality of patients with ITP in the current TPO-RA era. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.